Literature DB >> 16908509

Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis.

A Young1, G Koduri, M Batley, E Kulinskaya, A Gough, S Norton, J Dixey.   

Abstract

OBJECTIVE: To examine the cause of death in a large UK inception cohort of rheumatoid arthritis (RA), and whether this was related to disease duration and severity, treatment effects or extra-articular features and complications of RA.
METHODS: Standard clinical, laboratory, radiological and socio-economic measures were recorded at baseline and yearly in an inception cohort started in nine centres in 1986. Date and the cause of death were based on death certificates and the comparisons made with age and sex matched population figures. Risk factors for mortality were identified from baseline measures of disease.
RESULTS: There were 459 deaths (32%) in 1429 patients followed for up to 18 yrs. Standard mortality ratio was 1.27. Survival was significantly lower in the first 7 yrs of RA. Excess mortality was seen in cardiovascular disease (31%), pulmonary fibrosis (4%) and lymphoma (2.3%). Baseline predictors for mortality were men, older age, poor function, lower socio-economic status, extra-articular features, comorbidity, rheumatoid factor, X-ray erosions, high-ESR and low-haemoglobin.
CONCLUSION: There was a modest increase in mortality in RA, mainly in the first 7 yrs. Deaths from cardiovascular disease and pulmonary fibrosis were higher than expected, but treatment-related deaths were low. Risk factors included less favourable socio-economic status, markers of disease severity and diminished function within the first year.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908509     DOI: 10.1093/rheumatology/kel253

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  104 in total

1.  Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.

Authors:  Laura R Rekedal; Elena Massarotti; Rajesh Garg; Radhika Bhatia; Timothy Gleeson; Bing Lu; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2010-12

2.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

3.  Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses.

Authors:  Lisa Harlow; Bernadette R Gochuico; Ivan O Rosas; Tracy J Doyle; Juan C Osorio; Timothy S Travers; Carlos C Camacho; Chester V Oddis; Dana P Ascherman
Journal:  Clin Immunol       Date:  2014-08-19       Impact factor: 3.969

Review 4.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

5.  Incidence of malignancy in Japanese patients with rheumatoid arthritis.

Authors:  Toru Yamada; Ayako Nakajima; Eisuke Inoue; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

Review 6.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

7.  Modulation of autoimmune arthritis severity in mice by apolipoprotein E (ApoE) and cholesterol.

Authors:  P Alvarez; F Genre; M Iglesias; J J Augustin; E Tamayo; J C Escolà-Gil; B Lavín; F Blanco-Vaca; R Merino; J Merino
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

8.  Inhibiting interleukin-6 in rheumatoid arthritis.

Authors:  Ernest Choy
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

9.  Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.

Authors:  Jonathan Graf; Rebecca Scherzer; Carl Grunfeld; John Imboden
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.